Sign in Subscribe
Biochemistry

Cannabinoid Receptor 2 Agonists Show Potential in Treating HIV-Associated Neuroinflammation

Strategic Insights

— 1 min read

Researchers at the University of Pennsylvania have made a groundbreaking discovery in the fight against HIV/AIDS. According to their study, published in the Journal of Neuroimmune Pharmacology, cannabinoid receptor 2 (CB) agonists have shown promise in reducing HIV replication and inflammation in the central nervous system (CNS). The study found that CB activation reduced HIV replication in primary human monocyte-derived macrophages (MDMs) and human induced pluripotent stem cell-derived microglia (iMg) at differing doses. Additionally, CB agonism altered interferon and integrated stress response pathways in MDMs, and homeostatic pathways, including synapse maintenance and phagocytosis, in iMg.

Key Takeaways:

  • The study investigated the effects of cannabinoid receptor 2 (CB) agonists on HIV replication and inflammation in myeloid cells, including perivascular macrophages and microglia.
  • The researchers found that CB activation reduced HIV replication in primary human monocyte-derived macrophages (MDMs) and human induced pluripotent stem cell-derived microglia (iMg) at differing doses.
  • CB agonism altered interferon and integrated stress response pathways in MDMs, and homeostatic pathways, including synapse maintenance and phagocytosis, in iMg.
  • The study found that NLRP3 inflammasome activation, but not priming, was reduced by CB activation in iMg.
  • CB-specific agonists, such as JWH-133, were identified as promising candidates for the regulation of HIV-associated neuroinflammation.
  • The study was conducted by researchers at the University of Pennsylvania, including Sara Rathore, Alexander Starr, Marzieh Daniali, Peter J. Gaskill, and Kelly L. Jordan-Sciutto.
  • The research has been peer-reviewed and published in the Journal of Neuroimmune Pharmacology.

Statistics:

  • 87: The page number of the study in the Journal of Neuroimmune Pharmacology, Volume 20, Issue 1.
  • 20: The volume number of the Journal of Neuroimmune Pharmacology where the study was published.
  • 1: The issue number of the Journal of Neuroimmune Pharmacology where the study was published.
  • 2025: The year when the study was conducted.

Sources:

  • NewsRx LLC, "Researchers at University of Pennsylvania Report New Data on HIV/AIDS (Differential Effects of Cannabinoid Receptor 2 Agonists on HIV Replication and Inflammatory Activation in Monocyte-Derived Macrophages and Induced Pluripotent Stem ...)".
  • Journal of Neuroimmune Pharmacology, "Differential Effects of Cannabinoid Receptor 2 Agonists on HIV Replication and Inflammatory Activation in Monocyte-Derived Macrophages and Induced Pluripotent Stem Cell-Derived Microglia".
  • University of Pennsylvania, "Department of Oral Medicine, School of Dental Medicine".
  • Springer, "Journal of Neuroimmune Pharmacology".
  • Sara Rathore, "University of Pennsylvania, Dept. of Oral Medicine, School of Dental Medicine, 240 S. 40th St, Rm 312 Levy, Philadelphia, PA, 19104, United States".

Read more